Global vaccine group Gavi has $9bn — short of its target
The total, which Gavi announced at the end of the event, was less than targeted. It included new funding from governments and philanthropic donors, as well as money left after Covid-19 and other work. Gavi said more pledges were likely in the coming weeks.
Overall, the group was aiming to have $11.9bn (R209.97bn) for its work from 2026 to 2030 and wanted to raise at least $9bn at the summit without counting leftover money.
In an interview with Reuters, Gavi chief executive Sania Nishtar said the bulk of the total was new pledges but did not elaborate.
"In a very, very dire moment for global health ... This is far better than I had hoped it would be," said Nishtar.
The total did not include a pledge from the US. US health secretary Robert F Kennedy Jr said the US would no longer fund Gavi and accused it of ignoring vaccine safety, without citing any evidence.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TimesLIVE
2 days ago
- TimesLIVE
Somalia faces diphtheria surge amid vaccine shortages, aid cuts
Diphtheria cases and deaths have risen sharply this year in Somalia, where the response has been curtailed by vaccine shortages and US aid cuts, Somali officials said. More than 1,600 cases, including 87 deaths, have been recorded, up from 838 cases and 56 deaths in all of 2024, said Hussein Abdukar Muhidin, the general director of Somalia's National Institute of Health. Diphtheria, a bacterial disease that causes swollen glands, breathing problems and fever and mostly affects children, is preventable with a vaccine that became widely available in the mid-20th century. Childhood immunisation rates in Somalia have improved over the past decade, but hundreds of thousands of children are still not fully vaccinated. After fleeing fighting between government forces and Islamist militants in the central Somalia town of Ceeldheere three months ago, all four of Deka Mohamed Ali's children, none of whom was vaccinated, contracted diphtheria. Her nine-year-old daughter recovered, but her eight-year-old son died and two toddlers are now being treated at a hospital in the capital Mogadishu. "My children got sick and I just stayed at home because I did not know it was diphtheria," she told Reuters from the bedside of her three-year-old son Musa Abdullahi whose throat was swollen to the size of a lemon from the infection. Health minister Ali Haji Adam said the government had struggled to procure enough vaccines due to a global shortage and that US aid cuts were making it difficult to distribute the doses it had. Before President Donald Trump cut most foreign assistance earlier this year, the United States was the leading humanitarian donor to Somalia, whose health budget is almost entirely funded by donors. "The US aid cut terribly affected the health funds it used to provide to Somalia. Many health centres closed. Mobile vaccination teams that took vaccines to remote areas lost funding and now do not work," said Adam. Muhidin separately echoed his comments about the closures. Overall US foreign assistance commitments to Somalia stand at $149m (R2.63bn) for the fiscal year that ends on September 30, compared with $765m (R13.48bn) in the previous fiscal year, according to US government statistics. "The United States continues to provide lifesaving foreign assistance in Somalia," a US state department spokesperson said when asked about the impact of its aid cuts in the country. "America is the most generous nation in the world, and we urge other nations to dramatically increase their humanitarian efforts." Aid group Save the Children said last month that the closure of hundreds of health clinics in Somalia this year due to foreign cuts has contributed to a doubling in the number of combined cases of diphtheria, measles, whooping cough, cholera and severe respiratory infections since mid-April. Besides the US, UK, France, Germany and other major Western donors are also cutting aid budgets. Somalia's government has also faced criticism from doctors and human rights activists for its limited funding of the health sector. In 2024, it allocated 4.8% of its budget to health, down from 8.5% the previous year, Amnesty International said. The health ministry did not respond to a question about that criticism. It has said it is planning to launch a vaccination drive but has not given details when.
IOL News
13-08-2025
- IOL News
Glenmore's R2bn claims against health service providers dismissed by Competition Tribunal
The decision comes after the Tribunal upheld exceptions filed by both the National Health Laboratory Service (NHLS) and AfroCentric Health, citing multiple deficiencies in Glenmore's case. Image: Supplied The Competition Tribunal has ruled against Glenmore Capital, dismissing its complaint regarding the alleged exclusion of its COVID-19 rapid antigen test kits from the South African public and private sectors. The decision comes after the Tribunal upheld exceptions filed by both the National Health Laboratory Service (NHLS) and AfroCentric Health, citing multiple deficiencies in Glenmore's case. Glenmore's complaint, originally lodged with the Competition Commission in August 2022, sought damages nearing R2 billion, claiming that NHLS and AfroCentric engaged in exclusionary practices that barred it from entering the market for COVID-19 test kits. The Commission, however, chose not to pursue the case, citing Glenmore's struggle to achieve market acceptance as a result of commercial factors, including delays in regulatory approval and a decrease in demand as the COVID-19 pandemic waned. Frustrated with the Commission's decision, Glenmore escalated the matter to the Tribunal. At a pre-hearing in December 2024, Glenmore was afforded an opportunity to amend its founding affidavit to address the concerns raised by NHLS and AfroCentric. Despite making amendments, both defendants argued that Glenmore's case remained fundamentally flawed. Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Next Stay Close ✕ In its defence, NHLS and AfroCentric articulated four primary exceptions, asserting that Glenmore's complaint lacked a valid cause of action, failed to properly identify the legal entities involved, lacked a clear market definition, and exceeded the Tribunal's jurisdiction due to the nature of the claims made. No valid cause of action: Glenmore's complaint failed to establish a legal basis under the Competition Act, lacking both legal and factual foundation. Glenmore's complaint failed to establish a legal basis under the Competition Act, lacking both legal and factual foundation. Improper citation of entities: Glenmore did not adequately identify which legal entity allegedly contravened the Act, despite having been given several opportunities to rectify this. Lack of proper market definition: The complaint failed to clarify the relevant market, with Glenmore shifting references between disparate health products without defining a cohesive product or geographic market. The complaint failed to clarify the relevant market, with Glenmore shifting references between disparate health products without defining a cohesive product or geographic market. Lack of jurisdiction and procedural issues: The Tribunal highlighted that it cannot award damages unless under consent orders and noted allegations outside the ambit of competition law, such as irregular procurement and insider trading. The Tribunal noted that Glenmore had been granted ample opportunity to clarify and bolster its case but ultimately failed to provide a coherent argument. With the exceptions upheld, Glenmore's complaint referral was dismissed in its entirety. BUSINESS REPORT
TimesLIVE
11-08-2025
- TimesLIVE
Medical journal rejects Kennedy's call for retraction of vaccine study
An influential US medical journal is rejecting a call from US health secretary Robert F Kennedy Jnr to retract a large Danish study that found aluminium ingredients in vaccines do not increase health risks for children, the journal's editor told Reuters. Kennedy has long promoted doubts about vaccines' safety and efficacy and as health secretary has upended the federal government's process for recommending immunisation. A recent media report said he has been considering whether to initiate a review of shots that contain aluminium, which he said are linked to autoimmune diseases and allergies. The study, funded by the Danish government and published in July in the Annals of Internal Medicine, analysed nationwide registry data for more than 1.2-million children over more than two decades. It did not find evidence that exposure to aluminium in vaccines had caused an increased risk for autoimmune, atopic or allergic or neurodevelopmental disorders. The work is by far the best available evidence on the question of the safety of aluminium in vaccines, said Adam Finn, a childhood vaccination expert in the UK and paediatrician at the University of Bristol who was not involved in the study. "It's solid, [a] massive dataset and high-quality data," he said.
